
1. antimicrob agents chemother. 2015 aug;59(8):4719-26. doi: 10.1128/aac.00835-15.
epub 2015 may 26.

evidence plasmodium falciparum malaria multidrug resistance artemisinin and
piperaquine western cambodia: dihydroartemisinin-piperaquine open-label
multicenter clinical assessment.

leang r(1), taylor wr(2), bouth dm(3), song l(4), tarning j(4), char mc(1), kim
s(5), witkowski b(5), duru v(5), domergue a(5), khim n(5), ringwald p(6), menard 
d(7).

author information: 
(1)national centre parasitology, entomology malaria control, phnom penh, 
cambodia.
(2)national centre parasitology, entomology malaria control, phnom penh, 
cambodia service de médecine tropicale et humanitaire, hôpitaux universitaires de
genève, geneva, switzerland.
(3)national centre parasitology, entomology malaria control, phnom penh, 
cambodia world health organization, phnom penh, cambodia.
(4)mahidol oxford tropical medicine research unit, bangkok, thailand centre for
tropical medicine, university oxford, oxford, united kingdom.
(5)institut pasteur du cambodge, phnom penh, cambodia.
(6)world health organization, geneva, switzerland dmenard@pasteur-kh.org
ringwaldp@who.int.
(7)institut pasteur du cambodge, phnom penh, cambodia dmenard@pasteur-kh.org
ringwaldp@who.int.

western cambodia recognized epicenter plasmodium falciparum
multidrug resistance. recent reports efficacy dihydroartemisinin
(dha)-piperaquine (pp), latest artemisinin-based combination therapies
(acts) recommended who, prompted investigations. clinical
efficacy dihydroartemisinin-piperaquine uncomplicated falciparum malaria
was assessed western eastern cambodia 42 days. day 7 plasma
piperaquine concentrations measured day 0 isolates tested vitro
susceptibilities piperaquine mefloquine, polymorphisms k13 gene,
and copy number pfmdr-1 gene. total 425 patients recruited
in 2011 2013. proportion patients recrudescent infections was
significantly higher western (15.4%) eastern (2.5%) cambodia (p
<10(-3)). day 7 plasma pp concentrations median 50% inhibitory concentrations
(ic50) pp independent treatment outcomes, contrast median
mefloquine ic50, found lower isolates patients with
recrudescent infections (18.7 versus 39.7 nm; p = 0.005). significant
risk factor associated dha-pp treatment failure infection parasites
carrying k13 mutant allele (odds ratio [or], 17.5; 95% confidence interval
[ci], 1 308; p = 0.04). data show evidence p. falciparum resistance 
pp western cambodia, area widespread artemisinin resistance. new
therapeutic strategies, use triple acts, urgently needed and
must tested. (this study registered australian new zealand
clinical trials registry registration no. actrn12614000344695.).

copyright © 2015, american society microbiology. rights reserved.

doi: 10.1128/aac.00835-15 
pmcid: pmc4505193
pmid: 26014949  [indexed medline]

